View Older Stories View More Recent Stories

Aug 28, 2018 07:00AM BioTime’s CEO Adi Mohanty and CFO Russell Skibsted to Participate in Upcoming Panel and Conferences
Aug 16, 2018 08:04AM BioTime (BTX) Announces Acquisition of Patents & Patent Applications from Escape Therapeutics to Regulate Immune Tolerance
Aug 16, 2018 08:00AM AgeX Therapeutics Acquires Technology to Regulate Immune Tolerance
Aug 16, 2018 07:00AM BioTime to Present Data at the Military Health System Research Symposium
Aug 2, 2018 04:05PM BioTime Reports Second Quarter Results and Recent Corporate Accomplishments
Aug 2, 2018 08:00AM BioTime to Receive $43 Million From Juvenescence
Aug 2, 2018 07:00AM BioTime Announces the Start of an Investigator Initiated Study of Premvia™ Designed and Conducted by Dr. Gordon H. Sasaki
Aug 1, 2018 06:12PM BioTime Announces Distribution Ratio for Distribution of AgeX Therapeutics Shares
Jul 25, 2018 07:00AM Data from BioTime’s OpRegen® Program to Be Presented at AAO 2018
Jul 23, 2018 07:00AM BioTime to Announce Second Quarter 2018 Results on August 2, 2018
Jul 11, 2018 07:00AM AgeX Therapeutics CEO Dr. Michael D. West to Present at Ending Age-Related Diseases: Investment Prospects & Advances in Research, July 12 in New York City
Jul 10, 2018 07:00AM BioTime Announces July 31, 2018 Record Date for the Distribution of AgeX Therapeutics Shares
Jun 29, 2018 07:00AM BioTime Awarded Grant From the NIH
Jun 25, 2018 07:00AM BioTime Licenses GMP Cell Line to Goliver Therapeutics
Jun 11, 2018 07:00AM AgeX Therapeutics Closes on $5 Million Strategic Investment From Juvenescence
Jun 8, 2018 07:00AM BioTime Announces Submission of Draft Registration Statement for a Proposed Distribution of Its AgeX Shares
Jun 5, 2018 07:00AM AgeX Therapeutics Appoints John F. Mauldin to Board of Directors
May 30, 2018 07:00AM BioTime to Present at the 8th Annual LD Micro Invitational
May 29, 2018 07:05AM BioTime (BTX) Secures $1.9M Grant for Continued Development of OpRegen for Dry-AMD
May 29, 2018 07:00AM BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
May 24, 2018 07:00AM BioTime Further Expands OpRegen® Clinical Trial in Dry-AMD With the Opening of Two Additional U.S. Sites
May 17, 2018 07:00AM AgeX Therapeutics CEO Dr. Michael D. West to Deliver Keynote Address at World Advanced Therapies & Regenerative Medicine Congress, May 18 in London
May 10, 2018 04:05PM BioTime Reports First Quarter Results and Recent Corporate Accomplishments
May 2, 2018 07:00AM AgeX Announces NIH Grant Award
May 1, 2018 08:00AM BioTime Presents Updated OpRegen® Clinical Trial Data at ARVO
Apr 26, 2018 07:00AM BioTime to Announce First Quarter 2018 Results on May 10, 2018
Apr 16, 2018 07:00AM Data from BioTime’s OpRegen® and Retinal Restoration Programs to Be Presented at ARVO 2018
Apr 9, 2018 08:00AM Data from BioTime’s OpRegen® Program to Be Presented at the Fifth Annual Retinal Cell and Gene Therapy Innovation Summit
Mar 27, 2018 07:09AM BioTime (BTX) to Receive up to $3.5 million in Cash from Sale of Ascendance Biotechnology
Mar 27, 2018 07:00AM BioTime Announces Cash Sale of Ascendance Biotechnology
Mar 15, 2018 04:05PM BioTime Reports Fourth Quarter and Fiscal 2017 Results
Mar 13, 2018 08:00AM BioTime Submits CE Mark Application for European Approval of Renevia®
Mar 7, 2018 08:00AM BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial
Mar 5, 2018 08:00AM BioTime to Announce Fourth Quarter and Fiscal 2017 Results on March 15, 2018
Mar 1, 2018 08:00AM AgeX Therapeutics CEO Dr. Michael D. West to Present at Three Conferences in March 2018
Feb 28, 2018 08:00AM BioTime to Present at the Raymond James 39th Annual Institutional Investor Conference
Feb 26, 2018 07:00AM BioTime Announces Appointment of Gary S. Hogge, DVM, MS, PhD, as Sr. Vice President, Clinical and Medical Affairs
Feb 22, 2018 07:00AM BioTime Appoints Cavan Redmond to Its Board of Directors
Feb 15, 2018 07:00AM Data from BioTime's OpRegen® and Vision Restoration Programs to Be Presented at ARVO 2018
Feb 7, 2018 07:00AM BioTime to Participate at the BIO CEO and Investor Conference in New York, February 12th and 13th 2018
Jan 29, 2018 07:00AM Renevia® Data From the Successful Pivotal Trial to Be Presented at the IMCAS Conference
Jan 23, 2018 07:00AM BioTime to Present at the Noble Capital Markets 14th Annual Institutional Investor Conference in Fort Lauderdale, January 29, 2018
Jan 22, 2018 07:00AM BioTime Announces Clinical and Corporate Milestone Targets for 2018
Jan 18, 2018 07:00AM AgeX CEO Michael D. West to Present in Plenary Session at The World Stem Cell Summit on “Stem Cell Innovations That Will Change the World”
Jan 17, 2018 07:08AM BioTime (BTX) Announces Issuance of 41 New Patents
Jan 17, 2018 07:00AM BioTime Announces Issuance of 41 New Patents to Expand and Bolster Its Patent Estate
Jan 5, 2018 04:30PM AgeX Therapeutics to Present at Biotech Showcase Annual Conference
Jan 2, 2018 07:03AM BioTime (BTX) Publishes Study on Identification of Genes Implicated in Tissue Regeneration and Cancer
Jan 2, 2018 07:00AM AgeX Therapeutics Identifies Genes Implicated in Tissue Regeneration and Cancer
Dec 20, 2017 07:00AM BioTime to Participate in The LifeSci Advisors Corporate Access Event in San Francisco, January 8 – 10, 2018
View More Recent Stories View Older Stories